NASDAQ:NAMS NewAmsterdam Pharma Q4 2025 Earnings Results & Report $20.01 -0.18 (-0.89%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$20.01 0.00 (0.00%) As of 10/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NewAmsterdam Pharma missed analyst expectations on both earnings and revenue in its Q4 2025 results, released February 18, 2026. The company reported EPS of -$0.63 versus the -$0.40 consensus estimate, while revenue of $0.19 million fell short of the $0.92 million estimate by $0.73 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 18, 2026TimeBefore Market OpensConference Call7:00 AM ET NewAmsterdam Pharma EPS ResultsActual EPS-$0.63Consensus EPS -$0.40Beat/MissMissed by -$0.23One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersNewAmsterdam Pharma Revenue ResultsActual Revenue$0.19 millionExpected Revenue$0.92 millionBeat/MissMissed by -$730.00 thousandYoY Revenue GrowthN/AUpcoming EarningsNewAmsterdam Pharma's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K) NewAmsterdam Pharma Q4 2025 Earnings FAQ Did NewAmsterdam Pharma beat earnings estimates for Q4 2025? NewAmsterdam Pharma (NASDAQ:NAMS) reported earnings of -$0.63 per share for Q4 2025, missing the consensus estimate of -$0.40. The report was announced on Wednesday, February 18, 2026. What was NewAmsterdam Pharma's revenue for Q4 2025? NewAmsterdam Pharma reported revenue of $0.19 million for Q4 2025, against a consensus estimate of $0.92 million. When is NewAmsterdam Pharma's next earnings date? NewAmsterdam Pharma's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for NewAmsterdam Pharma on the company's earnings history page. NewAmsterdam Pharma Earnings HeadlinesDoes NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?October 14 at 7:31 AM | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Price Target of $49.00October 7, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Royal Bank Of Canada Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock PriceOctober 5, 2026 | americanbankingnews.comRBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative RiskOctober 5, 2026 | marketscreener.comMNewAmsterdam Pharma (NASDAQ:NAMS) Stock Falls 5.2% on Insider SellingOctober 4, 2026 | americanbankingnews.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities. Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia. NewAmsterdam has conducted late-stage clinical trials, including the BROADWAY and BROOKLYN studies, to evaluate the product’s efficacy and safety. As a clinical-stage company, NewAmsterdam does not yet have an approved commercial product. NewAmsterdam Pharma was established through the combination of businesses involved in the development of obicetrapib and became publicly traded on the Nasdaq under the symbol NAMS following a business combination with Frazier Lifesciences Acquisition Corporation in 2022. The company is led by Chief Executive Officer Michael Davidson, M.D., and conducts its clinical development activities across international markets.View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
